web analytics
23.7 C
Munich
Wednesday, June 29, 2022

Kaleido Biosciences Inc (OTCMKTS: KLDO) Making Moves Since Reversing Off $0.041 Lows

Kaleido Biosciences Inc (OTCMKTS: KLDO) is moving up steadily on a surge of volume on Tuesday as the stock comes back to life after 3 months of silence. The stock was de listed from the NASDAQ stock exchange after the Company reported it plans to discontinue its business operations. Since landing on the OTC KLDO has traded as low as $0.041 and was dormant for several months before the recent uptick. 

It’s very normal for ex NASDAQ stocks to make big moves once trading on the OTC. KLDO was trading for $9 per share this time last year and has come down a long way. The Company stated in their recent 10k they have initiated a process to explore a range of strategic alternatives to maximize shareholder value and have engaged professional advisors, including an investment banker to act as a strategic advisor for this process. Potential strategic alternatives that may be evaluated include a sale or merger of the Company or securing additional financing or partnerships that would enable further development of our programs.  

Kaleido Biosciences Inc (OTCMKTS: KLDO) is a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the microbiome to treat disease and improve human health. The Company has built a human-centric proprietary product platform for discovery and development that it believes will enable the advancement of a broad portfolio of novel product candidates. Kaleido Biosciences product candidates are Microbiome Metabolic Therapies (“MMT” or “MMTs”) which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The Company has an industrialized approach to the discovery and development of MMTs, and its initial MMTs are targeted glycans. Each targeted glycan is an ensemble of complex carbohydrates that is intended to modulate microbial metabolism and community composition to drive a specific biological response.  

To Find out the inside Scoop on KLDO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

KLDO

 

Kaleido Biosciences has initiated a process to explore a range of strategic alternatives to maximize shareholder value and have engaged professional advisors, including an investment banker to act as a strategic advisor for this process. Potential strategic alternatives that may be evaluated include a sale or merger of the Company or securing additional financing or partnerships that would enable further development of our programs. Kaleido Biosciences aims to run this strategic review process into mid-April 2022.  

The Company has developed proprietary synthetic chemistry technologies that allow it to create MMT candidates. Kaleido Biosciences believes the key characteristics of its MMT candidates include that they are orally administered, have limited systemic exposure and are selectively metabolized, structurally diverse, readily scalable, novel and proprietary. The Company believes that each of its MMT candidates works through one or more mechanisms of action, including selectively targeting the resident microbiome to restore gut-immune homeostasis. 

Utilizing its proprietary product platform, Kaleido Biosciences has created a library of more than 1,500 MMT candidates to probe the structure-activity relationships of its MMTs. Kaleido Biosciences MMT candidates and aspects of the proprietary product platform are supported by its expanding intellectual property portfolio, that includes fifteen U.S. patents, four European Patent Office, or EPO, patents and more than 115 non-provisional applications pending worldwide. 

For More on KLDO Subscribe Right Now!

Currently trading at a $2.2 million market valuation KLDO has 42,622,559 shares outstanding and has some revenues reporting over a million in sales over the past 3 months. The Company has $39 million in debt vs. $50 million in assets. It’s very normal for ex NASDAQ stocks to make big moves once trading on the OTC. KLDO was trading for $9 per share this time last year and has come down a long way. The stock may not be dead, the Company did state in their filings they are in the process to explore a range of strategic alternatives to maximize shareholder value and have engaged professional advisors, including an investment banker to act as a strategic advisor for this process. Potential strategic alternatives that may be evaluated include a sale or merger of the Company or securing additional financing or partnerships that would enable further development of its programs.  We will be updating on KLDO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with KLDO.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in KLDO either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.